Recent evidence on delamanid use for rifampicin-resistant tuberculosis.
作者信息
Pontali Emanuele, Centis Rosella, D'Ambrosio Lia, Toscanini Federica, Migliori Giovanni Battista
机构信息
Department of Infectious Diseases, Galliera Hospital, Genoa, Italy.
Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.
出版信息
J Thorac Dis. 2019 Mar;11(Suppl 3):S457-S460. doi: 10.21037/jtd.2018.11.26.
Abstract
摘要
相似文献
1
Recent evidence on delamanid use for rifampicin-resistant tuberculosis.近期关于地拉曼宁用于耐利福平结核病的证据。
J Thorac Dis. 2019 Mar;11(Suppl 3):S457-S460. doi: 10.21037/jtd.2018.11.26.
2
Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).地拉米定：从发现到用于治疗肺部耐多药结核病（MDR-TB）。
Tuberculosis (Edinb). 2018 Jul;111:20-30. doi: 10.1016/j.tube.2018.04.008. Epub 2018 May 3.
3
Delamanid for multidrug-resistant pulmonary tuberculosis.德拉马尼治疗耐多药肺结核。
N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433.
4
Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.地拉曼尼与贝达喹啉治疗儿童耐多药和广泛耐药结核病：一项系统评价
J Thorac Dis. 2017 Jul;9(7):2093-2101. doi: 10.21037/jtd.2017.06.16.
5
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.在德国，将新型或第5组干预措施添加到背景治疗方案中用于治疗耐多药结核病的成本效益。
BMC Health Serv Res. 2017 Mar 8;17(1):182. doi: 10.1186/s12913-017-2118-2.
6
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.德拉马尼联合优化背景治疗方案治疗耐多药结核病的疗效和安全性：一项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验。
Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7.
7
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.亚美尼亚、印度和南非采用贝达喹啉与德拉马尼联合治疗耐多药结核病患者的早期安全性和疗效：一项回顾性队列研究。
Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13.
8
Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.当其他抗结核治疗方案因耐药性或耐受性而失败时使用地拉米定。
Expert Opin Pharmacother. 2015 Feb;16(2):253-61. doi: 10.1517/14656566.2015.973853. Epub 2014 Oct 18.
9
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.比较硝基咪唑类药物德拉马尼和普托马尼对耐多药和广泛耐药结核病的体外活性。
Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1293-1296. doi: 10.1007/s10096-019-03551-w. Epub 2019 Apr 5.
10
Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.德拉马尼：在耐多药结核病患者中的应用评价。
Drugs. 2015 Jan;75(1):91-100. doi: 10.1007/s40265-014-0331-4.
引用本文的文献
1
Structure-Based Screening and Optimization of PafA Inhibitors with Potent Anti-Tuberculosis Activity.基于结构的具有强效抗结核活性的PafA抑制剂的筛选与优化
Int J Mol Sci. 2024 Dec 8;25(23):13189. doi: 10.3390/ijms252313189.
2
Progress in mechanism-based diagnosis and treatment of tuberculosis comorbid with tumor.结核病合并肿瘤的基于机制的诊断与治疗进展。
Front Immunol. 2024 Jan 17;15:1344821. doi: 10.3389/fimmu.2024.1344821. eCollection 2024.
3
The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives.耐药结核病治疗范式的转变：成功、陷阱与未来展望。
Clin Microbiol Rev. 2022 Dec 21;35(4):e0018019. doi: 10.1128/cmr.00180-19. Epub 2022 Oct 6.
4
Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis.系统测量联合用药格局以预测结核病的体内治疗结果。
Cell Syst. 2021 Nov 17;12(11):1046-1063.e7. doi: 10.1016/j.cels.2021.08.004. Epub 2021 Aug 31.
5
Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis.肺癌合并肺结核患者同时进行抗结核治疗与化疗的疗效及安全性
Ann Transl Med. 2020 Sep;8(18):1143. doi: 10.21037/atm-20-5964.
本文引用的文献
1
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.贝达喹啉与地拉曼尼联合治疗耐多药结核病：一项系统评价
Eur Respir J. 2018 Jul 4;52(1). doi: 10.1183/13993003.00934-2018. Print 2018 Jul.
2
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.德拉马尼治疗利福平耐药结核病：来自南非的回顾性研究。
Eur Respir J. 2018 Jun 14;51(6). doi: 10.1183/13993003.00017-2018. Print 2018 Jun.
3
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.亚美尼亚、印度和南非采用贝达喹啉与德拉马尼联合治疗耐多药结核病患者的早期安全性和疗效：一项回顾性队列研究。
Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13.
4
Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.贝达喹啉的心脏安全性：证据的系统与批判性分析
Eur Respir J. 2017 Nov 16;50(5). doi: 10.1183/13993003.01462-2017. Print 2017 Nov.
5
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.拉脱维亚接受含地拉曼尼方案治疗的耐多药和广泛耐药结核病患者的最终治疗结果
Eur Respir J. 2017 Nov 9;50(5). doi: 10.1183/13993003.01105-2017. Print 2017 Nov.
6
Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.韩国利奈唑胺治疗耐多药和广泛耐药结核病的中期结果。
J Antimicrob Chemother. 2018 Feb 1;73(2):503-508. doi: 10.1093/jac/dkx373.
7
Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.耐多药结核病或非结核分枝杆菌病患者使用致 QT 间期延长药物的临床意义。
Int J Tuberc Lung Dis. 2017 Sep 1;21(9):996-1001. doi: 10.5588/ijtld.17.0174.
8
Six-Month Response to Delamanid Treatment in MDR TB Patients.耐多药结核病患者使用德拉马尼治疗的六个月应答反应。
Emerg Infect Dis. 2017 Oct;23(10):1746-8. doi: 10.3201/eid2310.170468. Epub 2017 Oct 17.
9
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.贝达喹啉和德拉马尼联合治疗 5 例广泛耐药肺结核患者。
Emerg Infect Dis. 2017 Oct;23(10):1718-21. doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.
10
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.利奈唑胺治疗下耐多药和广泛耐药结核病患者的同情用药早期结果。
Eur Respir J. 2017 Jul 27;50(1). doi: 10.1183/13993003.00311-2017. Print 2017 Jul.
Zotero 插件